top of page
Cancer Blog
- Dr. Robert Nagourney -
Search


The Enormous Impact of EVA/PCD Chemosensitivity Testing in Patients with Rare Cancers: Durable Benefit Provided by An Unexpected Recommendation
The drug we recommended, Pazopanib, would not normally be expected to have activity in this rare and aggressive cancer.

Dr. Robert A. Nagourney, MD
Nov 32 min read


Non-Hodgkin's Lymphoma - Stage III: George Kalogridis
The information he received from the functional profile helped him find the right treatment regimen to save his life.

Dr. Robert A. Nagourney, MD
Mar 29, 20231 min read
bottom of page
